COLO B Coloplast A/S Class B

Coloplast A/S - Allocation of Share Options

Coloplast A/S - Allocation of Share Options

Report on transactions of executives and related parties in Coloplast shares and related securities

According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities.

The below transactions concern allocation of share options.

For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address:





  Details of the person discharging managerial responsibilities/person closely associated
a) Name Kristian Villumsen
2 Reason for the notification
a) Position/status President & CEO
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name Coloplast A/S (CVR-no.: 69749917)
b) LEI 529900NN7SOJ5QG82X67
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Share options relating to B shares
Identification code ISIN: DK0060448595 (B shares)
b) Nature of the transaction Share option allocation
c) Price and volume Price Volume
0.00 73,690
d) Aggregated information  
-        Aggregated volume 73,690 share options
-        Price DKK 0.00
e) Date of the transaction 2025-02-04, 12:10 UTC
f) Place of the transaction Outside a trading venue



 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Anders Lonning-Skovgaard
2 Reason for the notification
a) Position/status Executive Vice President & CFO
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name Coloplast A/S (CVR-no.: 69749917)
b) LEI 529900NN7SOJ5QG82X67
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Share options relating to B shares
Identification code ISIN: DK0060448595 (B shares)
b) Nature of the transaction Share option allocation
c) Price and volume Price Volume
0.00 37,511
d) Aggregated information  
-        Aggregated volume 37,511 share options
-        Price DKK 0.00
e) Date of the transaction 2025-02-04, 12:10 UTC
f) Place of the transaction Outside a trading venue

  

For further information, please contact

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel.

Aleksandra Dimovska

Vice President, Investor Relations

Tel. /

Email:

Simone Dyrby Helvind

Senior Manager, Investor Relations

Tel. /

Email:

Press and media

Peter Mønster

Sr. Media Relations Manager

Tel.

Email:

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebaek

Denmark

Company reg. (CVR) no. 69749917

Website

 

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail.

Coloplast was founded on passion, ambition, and commitment. We were born from a nurse’s wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-02.



All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachment



EN
04/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Rune Majlund Dahl
  • Rune Majlund Dahl

Coloplast (Hold, TP: DKK770.00) - Expecting another weak quarter

We expect another soft quarter (7.8% organic revenue growth YOY and a 27.5% EBIT margin), before then improving. We look for unchanged 2024/25 guidance of 8–9% organic sales growth and a c28% EBIT margin before special items. We have cut our 2024/25–2026/27e EPS by 2.8% on average and believe returning to a 30%+ EBIT margin hinges on external factors. We reiterate our HOLD, but have cut our target price to DKK770 (850).

 PRESS RELEASE

Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference...

Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference call on 6 May 2025 at 11.00am CEST Tuesday, 6 May 2025 at 11.00 - 12.00am CESTIn connection with the publication of Coloplast’s interim financial results for H1 2024/25, to be released same day around 07.30am CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the e...

Rune Majlund Dahl
  • Rune Majlund Dahl

Coloplast (Hold, TP: DKK850.00) - 2024/25 likely back-end loaded

The Q1 headline results were broadly in line with our forecasts and consensus. We view 2024/25 as back-end loaded and expect a pick-up in organic growth and margins over the coming quarters. The company maintained its 2024/25 guidance for 8–9% organic sales growth and a c28% EBIT margin before special items. We reiterate our HOLD and DKK850 target price.

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
 PRESS RELEASE

Coloplast A/S - Allocation of Share Options

Coloplast A/S - Allocation of Share Options Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address:   Details of the person discharging managerial responsibi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch